| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S17243 R72156 |
Al Khalaf (Controls unexposed, disease free), 2022 | Stillbirth | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, disease free excluded | Adjustment: No Indications Antihypertensive: Only chronic hypertension indication |
1.99 [1.24;3.22] C excluded (control group) |
17/1,952 7,631/1,739,944 | 7,648 | 1,952 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17244 R72163 |
Al Khalaf (Controls unexposed, sick), 2022 | Stillbirth | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, sick | Adjustment: No Indications Antihypertensive: Only chronic hypertension indication | 1.02 [0.59;1.73] C | 17/1,952 67/7,809 | 84 | 1,952 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S14346 R56769 |
Kayser, 2020 | Stillbirth | 2nd and/or 3rd trimester | prospective cohort | unexposed, disease free | Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified | 0.52 [0.03;10.95] C | 0/221 2/580 | 2 | 221 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S14281 R56175 |
Fidler, 1983 | Stillbirths (NOS) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free | Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified Matched | 0.38 [0.02;8.02] C | 0/50 2/96 | 2 | 50 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S14366 R56889 |
Redman, 1976 | Stillbirths | during pregnancy (anytime or not specified) | randomized controlled trial | unexposed, sick | Adjustment: Randomisation Indications Antihypertensive: All hypertensions, any indications or not specified | 1.06 [0.07;17.18] C | 1/101 1/107 | 2 | 101 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 4 studies | 0.97 [0.58;1.62] | 90 | 2,324 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, sick;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded 17243